5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | NEUTRAL | NEUTRAL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 16.51▲ | 16.77▼ | 16.77▼ | 17.45▼ | 16.53▲ |
MA10 | 16.59▲ | 16.93▼ | 16.93▼ | 17.05▼ | 16.08▲ |
MA20 | 16.78▼ | 17.36▼ | 17.40▼ | 16.72▼ | 16.18▲ |
MA50 | 17.46▼ | 17.26▼ | 17.13▼ | 15.93▲ | 18.03▼ |
MA100 | 17.38▼ | 17.08▼ | 16.75▼ | 16.24▲ | 19.90▼ |
MA200 | 17.19▼ | 16.69▲ | 16.85▼ | 18.09▼ | 16.71▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.017▲ | -0.098▼ | -0.111▼ | 0.020▲ | 0.268▲ |
RSI | 44.043▼ | 38.110▼ | 41.723▼ | 50.024▲ | 48.949▼ |
STOCH | 15.046▼ | 20.274 | 18.131▼ | 53.079 | 66.485 |
WILL %R | -56.250 | -74.900 | -79.872▼ | -68.448 | -34.137 |
CCI | -8.686 | -91.589 | -89.158 | 7.768 | 96.700 |
Tuesday, June 10, 2025 03:51 AM
Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases ...
|
Tuesday, May 13, 2025 05:01 PM
We have seen 17 institutional investors add shares of $PHVS stock to their portfolio, and 24 decrease their positions in their most recent quarter.
|
Tuesday, May 13, 2025 05:01 PM
We have seen 17 institutional investors add shares of $PHVS stock to their portfolio, and 24 decrease their positions in their most recent quarter.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 17.21 | 17.532 | 16.445 | 16.70 | 12,409 |
12/06/25 | 17.10 | 17.23 | 16.38 | 17.23 | 6,096 |
11/06/25 | 19.39 | 19.39 | 17.05 | 17.05 | 37,761 |
10/06/25 | 17.705 | 18.73 | 17.59 | 18.24 | 71,699 |
09/06/25 | 16.54 | 18.34 | 16.355 | 18.03 | 64,706 |
06/06/25 | 15.99 | 17.19 | 15.99 | 16.78 | 82,546 |
05/06/25 | 16.61 | 16.875 | 15.91 | 16.05 | 81,019 |
04/06/25 | 17.20 | 17.30 | 16.57 | 16.62 | 67,922 |
03/06/25 | 16.55 | 18.00 | 16.42 | 17.28 | 156,686 |
02/06/25 | 16.60 | 16.88 | 16.20 | 16.49 | 110,708 |
|
|
||||
|
|
||||
|
|